Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

Untreated Follicular Lymphoma and the Role of MRD Testing

July 9th 2019

Frontline Treatment for Follicular Lymphoma

July 9th 2019

Risk Stratification in Follicular Lymphoma

July 9th 2019

Treating Follicular Lymphoma: Addressing Unmet Needs

July 9th 2019

Treating Relapsed/Refractory Follicular Lymphoma

July 9th 2019

Obinutuzumab Versus Rituximab in Frontline FL

July 9th 2019

FL: Interpreting and Applying GALLIUM Data in Practice

July 9th 2019

The GALLIUM Study in Follicular Lymphoma

July 9th 2019

The National LymphoCare Study in Follicular Lymphoma

July 9th 2019

Frontline Treatment Regimens in Follicular Lymphoma

July 9th 2019

Initiating Therapy in Follicular Lymphoma

July 9th 2019

Risk Assessment for Patients With Follicular Lymphoma

July 9th 2019

Optimal Strategies to Help Diagnose Follicular Lymphoma

July 9th 2019

Expert Sorts Through Treatment Strategies in Follicular Lymphoma

July 2nd 2019

Chaitra S. Ujjani, MD, discusses the various therapeutic classes and agents that are showing the most promise in the field of follicular lymphoma.

Dr. Lugtenburg on Maintenance Rituximab in DLBCL

June 20th 2019

Pieternella J. Lugtenburg, MD, PhD, an internist and hematologist at Erasmus Medical Center in Rottenham, Netherlands, discusses the use of rituximab as maintenance therapy in patients with diffuse large B-cell lymphoma.

Optimal Upfront Lenalidomide/R-CHOP Use Remains Puzzle in DLBCL

June 20th 2019

Patients with activated B-cell-type diffuse large B-cell lymphoma with a poor prognosis may benefit from frontline treatment with lenalidomide plus standard R-CHOP, according to subgroup data from the phase III ROBUST trial presented at the 2019 International Conference on Malignant Lymphoma.

Dr. Vose on Acalabrutinib/Pembrolizumab Combo in DLBCL

June 19th 2019

Julia M. Vose, MD, professor and chief in the Division of Oncology/Hematology at University of Nebraska Medical Center discusses the rationale for the phase I/II trial of acalabrutinib (Calquence) plus pembrolizumab (Keytruda) in relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

FDA Approves Polatuzumab Vedotin for DLBCL

June 10th 2019

The FDA has granted an accelerated approval to polatuzumab vedotin (Polivy) for use in combination with bendamustine and rituximab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma.

Pipeline Updates Advance Paradigms Across Lymphomas

May 31st 2019

Matthew S. McKinney, MD, discusses exciting treatment advances made in Hodgkin and non-Hodgkin lymphoma, specifically the compelling research in follicular lymphoma and mantle cell lymphoma.

FDA Grants Copanlisib Breakthrough Designation for MZL

May 30th 2019

The FDA has granted copanlisib (Aliqopa) a breakthrough therapy designation for the treatment of adult patients with relapsed marginal zone lymphoma who have received at least 2 prior therapies.